Impact of breast cancer on anti-mullerian hormone levels in young women

Breast Cancer Research and Treatment

Volumn 137, Issue 2, 2013, Pages 571-577

  Su, H I ^a   Flatt, S W ^a   Natarajan, L ^a   Demichele, A ^b   Steiner, A Z ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

AMH; Breast cancer; Fertility preservation; Ovarian reserve

Indexed keywords

ESTROGEN RECEPTOR; FOLLITROPIN; INHIBIN B; MUELLERIAN INHIBITING FACTOR; PROGESTERONE RECEPTOR; INHIBIN;

ADULT; AGE; ARTICLE; BODY MASS; BREAST CARCINOMA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ETHNICITY; FEMALE; FERTILITY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OVARIAN RESERVE; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; RACE; SMOKING; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; FEMALE INFERTILITY; MULTIVARIATE ANALYSIS; OVARY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGE FACTORS; ANTI-MULLERIAN HORMONE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INFERTILITY, FEMALE; INHIBINS; MULTIVARIATE ANALYSIS; OVARY; YOUNG ADULT;

MLCS; MLOWN;

EID: 84880605150     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2361-5     Document Type: Article

References (36)

1. DevCan: Probability of Developing or Dying of Cancer Software VSRaABNCI, 2012. www.srab.cancer.gov/devcan
2. Warne GL, Fairley KF, Hobbs JB, Martin FI (1973) Cyclophosphamide-induced ovarian failure. N Engl J Med 289(22):1159-1162
3. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21(10):2583-2592
4. Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, Freeman EW, Gracia CR, DeMichele A (2010) Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116(3):592-599
5. Partridge AH, Gelber S, Peppercorn J, Ginsburg E, Sampson E, Rosenberg R, Przypyszny M, Winer EP (2008) Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer 8(1):65-69
6. Schover LR (2008) Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 26(5):753-758
7. Bahadur G, Ozturk O, Muneer A, Wafa R, Ashraf A, Jaman N, Patel S, Oyede AW, Ralph DJ (2005) Semen quality before and after gonadotoxic treatment. Hum Reprod 20(3):774-781
8. Bahadur G, Ling KL, Hart R, Ralph D, Wafa R, Ashraf A, Jaman N, Mahmud S, Oyede AW (2002) Semen quality and cryopreservation in adolescent cancer patients. Hum Reprod 17(12):3157-3161
9. Su HI (2010) Measuring ovarian function in young cancer survivors. Minerva Endocrinol 35(4):259-270
10. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB (2006) A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12(6):685-718
11. Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ (2007) Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril 87(4):764-775
12. La Marca A, Broekmans FJ, Volpe A, Fauser BC, Macklon NS (2009) Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod 24(9):2264-2275
13. Freeman EW, Sammel MD, Lin H, Gracia CR (2012) Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab 97(5):1673-1680
14. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, Stabile G, Volpe A (2010) Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16(2):113-130
15. Knopman JM, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F (2009) Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil Steril 91(4 Suppl):1476-1478
16. Quintero RB, Helmer A, Huang JQ, Westphal LM (2010) Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril 93(3):865-868
17. Robertson AD, Missmer SA, Ginsburg ES (2011) Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil Steril 95(2):588-591
18. Pal L, Leykin L, Schifren JL, Isaacson KB, Chang YC, Nikruil N, Chen Z, Toth TL (1998) Malignancy may adversely influence the quality and behaviour of oocytes. Hum Reprod 13(7):1837-1840
19. Domingo J, Guillen V, Ayllon Y, Martinez M, Munoz E, Pellicer A, Garcia-Velasco JA (2012) Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 97(4):930-934
20. Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF 3rd (2007) Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril 87(1):101-106
21. Efron BT, Tibshirani RJ (1994) An introduction to the bootstrap. CRC Press, Boca Raton
22. Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S, Baird DD (2010) Antimullerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet Gynecol 117(4):798-804
23. Das M, Shehata F, Moria A, Holzer H, Son WY, Tulandi T (2011) Ovarian reserve, response to gonadotropins, and oocyte maturity in women with malignancy. Fertil Steril 96(1):122-125
24. Moria A, Das M, Shehata F, Holzer H, Son WY, Tulandi T (2011) Ovarian reserve and oocyte maturity in women with malignancy undergoing in vitro maturation treatment. Fertil Steril 95(5):1621-1623
25. Yu B, Douglas N, Ferin MJ, Nakhuda GS, Crew K, Lobo RA, Hershman DL (2010) Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116(9):2099-2105
26. Lawrenz B, Fehm T, von Wolff M, Soekler M, Huebner S, Henes J, Henes M (2012) Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma-evaluation by using antimullerian hormone and retrieved oocytes. Fertil Steril 98(1):141-144
27. Plante BJ, Cooper GS, Baird DD, Steiner AZ (2010) The impact of smoking on antimullerian hormone levels in women aged 38-50 years. Menopause 17(3):571-576
28. Hehenkamp WJ, Volkers NA, Broekmans FJ, de Jong FH, Themmen AP, Birnie E, Reekers JA, Ankum WM (2007) Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 22(7):1996-2005
29. La Marca A, Stabile G, Artenisio AC, Volpe A (2006) Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 21(12):3103-3107
30. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y (2007) Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 22(7):1837-1840
31. Li HW, Anderson RA, Yeung WS, Ho PC, Ng EH (2011) Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea. Fertil Steril 96(3):774-779
32. Nelson SM, La Marca A (2012) The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 23(4):411-420
33. Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE (2010) Development of a second generation anti-Mullerian hormone (AMH) ELISA. J Immunol Methods 362(1-2):51-59
34. Lee JR, Kim SH, Jee BC, Suh CS, Kim KC, Moon SY (2011) Antimullerian hormone as a predictor of controlled ovarian hyperstimulation outcome: comparison of two commercial immunoassay kits. Fertil Steril 95(8):2602-2604
35. Streuli I, Fraisse T, Chapron C, Bijaoui G, Bischof P, de Ziegler D (2009) Clinical uses of anti-Mullerian hormone assays: pitfalls and promises. Fertil Steril 91(1):226-230
36. Freour T, Mirallie S, Bach-Ngohou K, Denis M, Barriere P, Masson D (2007) Measurement of serum anti-Mullerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta 375(1-2):162-164